Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 1,183.6% in July

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 191,579 shares, a growth of 1,183.6% from the June 30th total of 14,925 shares. Based on an average trading volume of 394,403 shares, the short-interest ratio is currently 0.5 days. Approximately 0.0% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Daiichi Sankyo has a consensus rating of “Hold”.

Daiichi Sankyo Trading Up 1.4%

Shares of OTCMKTS:DSNKY traded up $0.24 on Friday, reaching $17.25. 146,211 shares of the company traded hands, compared to its average volume of 236,275. The business’s 50-day simple moving average is $16.42 and its 200 day simple moving average is $17.91. Daiichi Sankyo has a 52 week low of $14.98 and a 52 week high of $27.50. The stock has a market capitalization of $32.13 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 3.02 and a beta of -0.17. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, equities analysts anticipate that Daiichi Sankyo will post 0.96 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.